三生国健(688336) - 2024 Q4 - 年度业绩预告

Revenue and Profit Projections - The company expects to achieve operating revenue of between CNY 1,145.48 million and CNY 1,228.44 million for 2024, representing a year-on-year increase of CNY 131.45 million to CNY 214.40 million, or a growth of 12.96% to 21.14%[4]. - The projected net profit attributable to the parent company for 2024 is between CNY 700.40 million and CNY 771.90 million, an increase of CNY 405.78 million to CNY 477.29 million compared to the previous year, reflecting a growth of 137.73% to 162.00%[4]. - The expected net profit attributable to the parent company after deducting non-recurring gains and losses is projected to be between CNY 238.79 million and CNY 278.59 million, an increase of CNY 32.17 million to CNY 71.97 million, or a growth of 15.57% to 34.83%[4]. - The previous year's net profit attributable to the parent company was CNY 294.61 million, with a total profit of CNY 310.63 million[10]. - The company reported earnings per share of CNY 0.48 for the previous year[11]. Research and Development Investment - The company plans to invest between CNY 522.96 million and CNY 558.96 million in R&D for 2024, which is an increase of CNY 208.77 million to CNY 244.77 million, representing a growth of 66.45% to 77.91% compared to the previous year[5]. - The capitalized R&D expenses are expected to be between CNY 341.49 million and CNY 371.49 million, an increase of CNY 59.19 million to CNY 89.19 million, reflecting a growth of 20.97% to 31.59%[5]. Special Dividend and Performance Forecast - The company received a special dividend distribution of USD 6.24 million (approximately CNY 446.55 million) from its associate Numab Therapeutics, AG, positively impacting the 2024 operating performance[12]. - The performance forecast is based on preliminary calculations by the finance department and has not been audited by a registered accountant[9]. - The company does not foresee any significant uncertainties that could affect the accuracy of this performance forecast[13].